Company intelligence / Profile preview

Merlin Biotech

Doylestown, Pennsylvania, USAmerlinbiotech.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Merlin Biotech’s lead asset, MER-101, uses proprietary mRNA encoding the USP6 protein to activate multiple immunostimulatory pathways for cancer immunotherapy. Preclinical data show anti-tumor activity in both injected tumors and distant lesions. The company also has programs targeting chronic hepatitis B and Lyme disease. No clinical trial results have been published yet; all programs are pre-clinical as of 2024.

Therapeutic areas: OncologyInfectious Diseases
Modalities: mRNA-based therapeutics and vaccines
Industry: Biotech

Drug pipeline

2 assets

MER-101

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Merlin Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Merlin Biotech.

Explore the full profile